Email This Article

Headlines & Perspectives
Amgen to Review Business with Analysts
By Elizabeth Trotta
11/06/08 - 12:20 PM EST
Amgen executives are expected to open up about their potential blockbuster bone-drug denosumab, or Dmab, and the company's pipeline at a business-review meeting on Friday.
Recipient's Email Address(es)
(Separate multiple addresses with a comma)
Your Email Address
Send a copy to myself
Your Message (optional)

Privacy Policy

The information entered on this page will not be used to send unsolicited email and will not be sold to a 3rd party.

Dow Jones S&P 500 NASDAQ 10-Year Note
10,304.18 1,091.54 2,138.77 32.27
Oil *
75.94
DOWN
160.22
DOWN
19.09
DOWN
37.28
DOWN
0.52
10 Yr
3.23%
SPDR Gold
114.24
-1.53%
-1.72%
-1.71%
-1.59%
Data delayed 20 minutes

Brokerage Partners